Piper Sandler analyst Adam Maeder maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $260.00. The company’s shares closed yesterday at $257.65.
In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback